Orgenesis Inc. (ORGS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.6900

-0.0800

(-4.52%)

At close: 04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	1.7700
Open	1.7400
Bid	1.5000 x 1200
Ask	1.7400 x 1000
Day's Range	1.6700 - 1.7900
52 Week Range	1.5700 - 5.4300
Volume	58,995
Avg. Volume	39,590

Market Cap	43.172M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8960
Earnings Date	Nov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ORGS

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Orgenesis Inc.
Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.
Rating
Fair Value
Economic Moat
6 days agoArgus Research

All

GlobeNewswire
Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022
Secures Funding from Metalmark Capital Partners to Drive Growth Orgenesis to Host Conference Call Today, August 16, 2022 at 11 AM Eastern Time GERMANTOWN, Md., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for second quarter ending June 30, 2022. Vered Caplan, CEO of Orgenesis, said, “We are progressing with our transit
- Tribe Property Technologies Announces Timing of Second Quarter 2022 Results & Conference Call
  CNW Group
- Canadian Manganese Reports Second Quarter 2022 Results
  Newsfile
GlobeNewswire
Orgenesis Schedules Second Quarter 2022 Business Update Conference Call
GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 fo
GlobeNewswire
Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022
GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today provided a business update for first quarter ended March 31, 2022. Recent highlights: Expanded POCare with Johns Hopkins University through creation of the Maryland Center for Cell Therapy ManufacturingReached milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madr